Management of Isolated Interstitial Kidney Disease with Normal Glomeruli
When renal biopsy shows normal glomeruli with isolated interstitial disease (acute interstitial nephritis), immediately discontinue any offending medications and initiate corticosteroid therapy if there is significant tubular dysfunction or progressive kidney injury.
Diagnostic Approach
The finding of normal glomeruli on biopsy indicates that the primary pathology lies in the tubulointerstitium rather than the glomerular compartment. This fundamentally changes your management strategy:
Key Clinical Features to Assess
- Tubular dysfunction markers: Look for non-oliguric acute kidney injury with modest but gradual creatinine increments, glycosuria despite normal glucose, mild proteinuria (<2 g/day), and microscopic hematuria 1, 2
- Medication history: Drugs account for 70% of acute interstitial nephritis (AIN) cases, with over 150 agents implicated 2
- Systemic manifestations: Check for fever, rash, eosinophilia (though these classic findings are present in <10% of cases), uveitis, or elevated gamma-globulins 2, 3
Treatment Algorithm
Step 1: Remove the Offending Agent
The cornerstone of management is identifying and eliminating the causative factor—whether medication, infection, or systemic disease 1, 2, 4.
Step 2: Corticosteroid Therapy Decision
Initiate corticosteroids when:
- Progressive kidney injury despite removal of offending agent
- Significant tubular dysfunction present
- Early diagnosis (within days to weeks of onset)
Corticosteroid regimen (based on meta-analysis showing improved renal outcomes 1):
- Prednisolone 0.5-1 mg/kg/day (typically 40-60 mg daily)
- Duration: 4-8 weeks with gradual taper
- Earlier initiation (within 7-14 days) associated with better outcomes 2, 4
Step 3: Monitor Response
Complete resolution occurs in approximately 65% of cases, partial resolution in 20%, and irreversible damage in the remainder 2. Serial monitoring of:
- Serum creatinine and eGFR
- Urinary markers of tubular function
- Proteinuria levels
Critical Pitfalls to Avoid
Do not assume irreversibility based solely on interstitial fibrosis: While severe interstitial fibrosis and tubular atrophy (IFTA) is a strong predictor of kidney failure, some patients with severe fibrosis will not progress within 5 years. Treatment should be considered when risks are reasonable despite lower potential benefit 5.
Do not delay biopsy in unexplained AKI: The key to early diagnosis is vigilance for tubular dysfunction in non-oliguric patients with modest creatinine increments. Early recognition and treatment lead to better outcomes 2, 4.
Do not overlook the tubulointerstitial compartment: The glomerulo-interstitial inflammatory axis is increasingly recognized as critical for CKD progression. Tubulointerstitial inflammation serves as a nexus connecting injury to fibrosis and function decline 6.
When Immunosuppression May Not Be Indicated
- Chronic interstitial nephritis with extensive fibrosis (>50% cortical involvement) and no active inflammation
- Stable kidney function after removal of offending agent
- Secondary causes adequately treated (e.g., resolved infection)
Special Considerations
For steroid-refractory cases, mycophenolate mofetil has been evaluated as an alternative, though evidence remains limited 1. The decision to escalate therapy should weigh the severity of kidney injury against immunosuppression risks.
Adverse events from corticosteroids are likely underreported in the literature, emphasizing the need for careful patient selection and monitoring 1.
The evidence supporting corticosteroid use, while showing benefit in meta-analysis 1, demonstrates significant variability in dosing, duration, and timing across studies. High-quality randomized controlled trials are needed to establish definitive evidence-based protocols 1.